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AbstrACt
Objectives There is a mismatch between research 
questions considered important by patients, carers and 
healthcare professionals and the research performed in 
many fields of medicine. The non-alcohol-related liver 
and gallbladder disorders priority setting partnership 
was established to identify the top research priorities in 
the prevention, diagnostic and treatment of gallbladder 
disorders and liver disorders not covered by the James-
Lind Alliance (JLA) alcohol-related liver disease priority 
setting partnership.
Design The methods broadly followed the principles 
of the JLA guidebook. The one major deviation from 
the JLA methodology was the final step of identifying 
priorities: instead of prioritisation by group discussions 
at a consensus workshop involving stakeholders, the 
prioritisation was achieved by a modified Delphi consensus 
process.
results A total of 428 unique valid diagnostic or 
treatment research questions were identified. A literature 
review established that none of these questions were 
considered ‘answered’ that is, high-quality systematic 
reviews suggest that further research is not required on 
the topic. The Delphi panel achieved consensus (at least 
80% Delphi panel members agreed) that a research 
question was a top research priority for six questions. 
Four additional research questions with highest proportion 
of Delphi panel members ranking the question as highly 
important were added to constitute the top 10 research 
priorities.
Conclusions A priority setting process involving patients, 
carers and healthcare professionals has been used to 
identify the top 10priority areas for research related to 
liver and gallbladder disorders. Basic, translational, clinical 
and public health research are required to address these 
uncertainties.
IntrODuCtIOn 
Failure to address treatment uncertainties 
by research can lead to significant suffering 
and deaths.1 It is important that research 
in any field of medicine takes into account 
the shared interests of patients, carers and 
clinicians.2 However, there is a mismatch 
between research questions that are consid-
ered important jointly by patients, carers and 
healthcare professionals and the research 
performed in many fields of medicine.3 4 
The James-Lind Alliance (JLA) exists to help 
ensure a patient-centred process and enables 
the limited research resources to be used in 
addressing the research questions that are 
considered important jointly by patients, 
carers and healthcare professionals2 (‘top 
research priorities’). This is achieved by 
forming ‘priority setting partnerships’ 
(PSPs) between patients, carers and health-
care professionals.2 Formal prioritisation of 
research topics jointly by patients and health-
care professionals can lead to increased 
research on the topic.5 6 
There has only been one formal research 
prioritisation process involving patients, carers 
and healthcare professionals in the field of liver 
and gallbladder disorders.7 However, the scope 
of that PSP was limited to alcohol-related liver 
disorders.7 The Non-Alcohol-Related Liver and 
gallbladder disorders Priority setting partner-
ship (NARLIP) was established to address the 
strengths and limitations of this study
 ► A research prioritisation process involving clini-
cians, patients and carer, and public representatives 
was performed in the field of liver and gallbladder 
disorders. This will help to address the mismatch 
between research questions that are considered 
important jointly by patients, carers and healthcare 
professionals and the research performed in the 
field of liver and gallbladder disorders.
 ► A Delphi consensus method was performed. This 
prevented dominance of ‘loud voices’, a problematic 
issue with small and large group discussions.
 ► Because of the predominance of people with chronic 
liver disease on the Delphi panel, many of the top 
research priorities related to chronic liver diseases.
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prevention, diagnostic and treatment uncertainties related 
to the majority of liver disorders which were not covered 
by the JLA PSP on alcohol-related liver diseases7 and to 
include gallbladder disease.
The aims and objectives of the NARLIP were to work 
with patients, their carers and healthcare professionals 
treating them (‘stakeholders’) to identify uncertainties 
about the diagnostic tests and effects of prevention and 
treatments for non-alcohol-related liver and gallbladder 
disorders, to agree by consensus a prioritised list of those 
uncertainties for research, to publicise the results and 
process, and to take the results to research commissioning 
bodies to be considered for funding and researchers to 
encourage them to submit grant applications addressing 
these uncertainties.
MethODs
The methods broadly followed the principles of the JLA 
guidebook.8 The broad steps involved the following and 
are summarised in figure 1.
1. Formation of the partnership: organisations and in-
dividuals representing people affected by non-alco-
hol-related liver or gallbladder disorders, their carers 
and healthcare professionals treating people with 
non-alcohol-related liver and gallbladder disorders. 
A partnership was formed between KG representing 
University College London and the British Liver Trust 
initially, but following reorganisation in the British 
Liver Trust, PSC Support9 became the leading patient 
organisation partner of this process. A steering com-
mittee was formed. The members of the steering com-
mittee who participated in the complete process were 
KG, MW, BRD, CF, BF, AM, RM, SM, IS and ET.
2. Establishment of the scope: the steering committee 
members discussed and decided that the scope should 
include adult and paediatric liver and gallbladder 
disorders which required medical and surgical treat-
ments. The protocol was registered with JLA  PSP.
3. Identifying potential research questions: research 
questions were collected through online surveys and 
searching UK Database of Uncertainties about the Ef-
fects of Treatments (UK DUETs), research recommen-
dations in high-quality systematic reviews and clinical 
guidelines, and registers of ongoing research.
4. Refining research questions: the research questions 
identified in the above step were reviewed and where 
necessary combined to result in a set of unique re-
search questions. Research questions were considered 
‘answered’ when recent high-quality systematic reviews 
(based on low risk of bias studies) concluded that fur-
ther research was not required. Removal of such ‘an-
swered’ research questions was planned. The remain-
ing questions were ‘uncertainties’.
5. Interim prioritisation: to shortlist the set of questions 
to manageable levels for the final prioritisation pro-
cess, the members of the steering committee ranked 
the uncertainties after stratifying the questions as med-
ical and surgical questions. The members of the steer-
ing committee agreed that the interim prioritisation 
list should consist of 75% medical questions and 25% 
surgical questions. This decision was an arbitrary de-
cision made by the steering committee based on the 
rationale that majority of individuals with liver and 
gallbladder disorders are treated medically but a mi-
nority require surgery which have a major impact on 
patients’ lives.
6. Final prioritisation by consensus: a modified Delphi 
consensus method was followed to identify the top pri-
orities using methods described by Jones and Hunter.10 
The Delphi was performed electronically using Excel 
for managing the process. The steps in the modified 
Delphi consensus method were as follows.
a. A Delphi panel consisting of patients, their carers 
and healthcare professionals treating them was 
formed. The Delphi panel was formed by using 
‘snowballing’ sampling methods and by contacting 
people through emails, online liver patient forums 
(British Liver Trust Health Unlocked forum) and 
Figure 1 The major steps in the research prioritisation 
are shown in the figure. aThe protocol was registered with 
James-Lind Alliance (JLA) priority setting partnership (PSP). 
bThe final prioritisation was achieved by modified Delphi 
consensus method.
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newsletters. A total of 42 people expressed interest 
in joining the Delphi panel and 33 panel members 
completed all three rounds. Details of the Delphi 
panel composition and drop-outs are reported in 
the results section.
b. A total of three rounds were conducted.
c. Delphi panel members scored the shortlisted ques-
tions in the interim prioritisation process on a scale 
of 1–9 with 1 being considered least important and 
9 being considered most important. Scores of 1–3 
were categorised as ‘less important’, 4–6 as ‘mod-
erately important’ and 7–9 as ‘highly important’. 
Panel members were requested to score the ques-
tions according to the importance of the question 
to them/the persons that they represent or treat 
and could leave questions that they were unable 
to score empty. Each Delphi panel member could 
add a maximum of two questions in the first round 
to ensure that the questions most important to the 
Delphi panel members were included in the pri-
oritisation process even if they were not identified 
in the earlier steps. In the subsequent rounds, the 
panel members were shown the summary scores 
and their previous score for each question. They 
were able to retain or change their score in each 
of the rounds after the first round. For calculation 
of the summary scores and the proportion consid-
ering a question ‘highly important’, non-responses 
were excluded.
d. Consensus about a specific research question be-
ing a top research priority was reached when 80% 
or more Delphi panel members considered the 
research question as highly important (allocated 
scores between 7 and 9).
e. When fewer than 10 research priorities were ob-
tained by consensus, the remaining priorities were 
completed by uncertainties based on the highest 
proportions of panel members agreeing that the 
research question was highly important (scores be-
tween 7 and 9).
f. There was no restriction on the Delphi panel to 
consult others while scoring the questions. Howev-
er, only one final response on the set of questions 
was accepted from each Delphi panel member.
When there were no recent high-quality systematic 
reviews on the research question, we have recommended 
high-quality systematic reviews. When recent high-quality 
systematic reviews recommended high-quality research, 
we have recommended randomised controlled trials 
(RCTs) for prevention and treatment, as such studies 
carry the lowest risk of bias if conducted well; we would 
have recommended well conducted diagnostic test 
accuracy studies for diagnostic uncertainties. All online 
surveys were completed using Google Forms designed by 
KG. The Delphi process was completed using Microsoft 
Excel and email.
In addition, we had full support of patient organisations 
with involvement of patient representatives throughout 
the whole process rather than patients visiting the 
hospitals.
Patient and public involvement
Patients and public were involved in all aspects of this 
project: they were part of the steering committee and 
were involved in the definition of the scope, method-
ology used for the prioritisation process, identification of 
further patients and public representatives, participation 
in the Delphi panel, interpretation and critical revisions 
of the draft report. They will be involved in the dissemi-
nation of the findings through patient websites, patient 
forums and to research funders.
results
Identifying and refining of research uncertainties
A total of 126 patients, carers, and those at risk of devel-
oping non-alcohol-related liver and gallbladder disorders, 
and 13 healthcare professionals participated in the first 
survey which was conducted between July and December 
2015. This survey resulted in a total of 209 unique research 
questions. In addition, 219 unique questions were identi-
fied from searching the UK DUETs, Pubmed and  Clinical-
Trials. gov on 2 January 2016. A total of 428 unique valid 
(ie, falling within the remit of this priority setting part-
nership) research questions (247 medical-related and 181 
surgery-related) were identified from these sources. None 
of the research questions had been answered by recent 
high-quality systematic reviews based on low risk of bias 
studies which concluded that further research was not 
required. Therefore, all the 428 research questions were 
considered research ‘uncertainties’. The complete list of 
428 unique valid uncertainties in no particular order is 
available in online supplementary appendix 1. This has 
been converted to the population, intervention, control 
and outcomes format whenever possible.
Interim priorities
To identify a shortlist of questions (from the list of 429 
questions) that were to be considered for the next step, a 
total of 48 research priorities (36 medical questions and 
12 surgical questions) were identified on the basis of being 
selected by at least one patient or carer and healthcare 
professional of the steering committee (24 questions) 
and obtaining the highest ranks among the members of 
the steering committee (additional 24 questions). The 
list of 48 questions identified as interim priorities in no 
particular order is available in online supplementary 
appendix 2.
Final priorities
A total of 42 people expressed interest in joining the 
Delphi panel and 33 panel members completed all three 
rounds. Five people dropped out before they returned the 
scores of the first round (all patients, carers and general 
public), three between first and second rounds (all 
healthcare professionals) and one between the second 
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and third rounds (healthcare professional). Of the 33 
panel members who completed all the three rounds, 17 
were healthcare professionals and 16 were patients, carers 
and general public. Of the 17 healthcare professionals, 
six were hepatologists, four were surgeons, two were 
hepatology nurses and the remaining were general prac-
titioner, hepato-pancreato biliary surgery nurse, organ 
preservation biologist, dietician and pharmacist (one 
each). Of the 16 patients, carers and general public, there 
was representation from general public and various liver 
diseases including autoimmune diseases such as primary 
sclerosing cholangitis (PSC), primary biliary cholangitis, 
autoimmune hepatitis, viral hepatitis, metabolic diseases 
such as non-alcohol-related fatty liver disease (NAFLD), 
and other diseases such as hepatocellular carcinoma and 
polycystic liver disease. There was also representation of 
liver transplanted patients in the Delphi panel. In total, 
23 panel members were from England, seven were from 
Scotland and three were from Wales. There were no 
panel members from Northern Ireland despite attempts 
to include panel members from Northern Ireland.
A total of 22 additional questions were added by the 
Delphi panel members in the first round of the Delphi 
process. The Delphi panel achieved consensus that an 
uncertainty was a top research priority for six research 
questions. Four additional research questions with the 
highest proportion of Delphi panel members scoring the 
question as highly important (scores between 7 and 9) 
were added to constitute the top 10 research priorities. 
The list of the top 10 research priorities (in the order 
of proportion who agreed that the uncertainty is a very 
important research priority) is available is table 1. All 
the top 10 research priorities were prevention and treat-
ment uncertainties, and none were diagnostic test uncer-
tainties. None of the panel members thought the first 
two questions as least important (scores 1–3). For the 
remaining eight questions, 3%–6.5% of people consid-
ered the questions to be least important (scores 1–3).
A summary of the availability of systematic review of 
RCTs on the topic of the individual questions, RCTs on 
the topic not included in the systematic review (if one 
exists), and the outcomes evaluated in these RCTs are 
listed in table 2. Table 2 also contains a suggestion for 
the next research steps. The list of the existing trials was 
compiled by searching  ClinicalTrials. gov on 7 April 2018. 
The references to the trials not included in the systematic 
reviews is available in online supplementary appendix 3. 
As seen in table 2, a well-designed RCT is the next step for 
eight of these top 10 research questions. This is because it 
appears that the outcomes in those trials will not address 
the outcomes listed in the research questions.
The complete list of questions in the Delphi process, 
the proportion of respondents who considered a research 
question as very important and the summary scores in 
each Delphi round is available in online supplementary 
appendix 4. This appendix also has the breakdown of the 
proportion of patients, carers and general public who 
considered a research question as very important and 
Table 1 Treatment uncertainties for which consensus that the uncertainty is a research priority was reached
Treatment uncertainty (research question)
Proportion 
who rated this 
question as highly 
important in the 
final round
Median (IQR) in 
the final round
What is the best treatment for people with early or very early hepatocellular carcinoma? 93.5% 8 (7,9)
What are the best treatments that cure or delay the progression (worsening) of primary 
sclerosing cholangitis (PSC)?
93.3% 8 (7,9)
What are the best treatments that cure or delay the progression (worsening) of non-
alcohol-related fatty liver disease (NAFLD)?
90.3% 9 (8,9)
What is the best immunosuppressive regimen in adults undergoing liver 
transplantation?
90.3% 8 (7,9)
Should general public be educated about NAFLD with an aim to reduce the numbers of 
those that have it?
81.8% 8 (7,9)
What are the best treatments that cure or delay the progression (worsening) of 
autoimmune hepatitis?
80.6% 8 (7,9)
What are the best treatments that cure or delay the progression (worsening) of non-
alcohol-related steatohepatitis?
76.7% 8 (6.75,9)
Prior to liver transplantation, is it better to transport the donor liver using a machine 
which pumps blood or preservation solution through the liver (machine perfusion) 
or is it better to transport it in the standard way of transporting it immersed in cold 
preservation solution (cold storage)?
74.2% 7 (6,9)
What are the best treatments that cure or delay the progression (worsening) of primary 
biliary cholangitis?
74.2% 7 (6,8)
Are there any treatments that reverse the liver damage in PSC? 72.4% 7 (6,9)
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Table 2 Next step to address the top 10 research priorities based on current best evidence (summary)
Treatment uncertainty 
(research question)
High-quality 
systematic review*†
RCTs not included 
in the systematic 
review*‡
Patient-oriented 
outcomes assessed in 
trials not included in the 
systematic review§ Next step
What is the best 
treatment for people 
with early or very 
early hepatocellular 
carcinoma (HCC)?
13 8 trials Survival (7 trials), recurrence 
(5 trials), morbidity (3 trials)
High-quality RCTs 
of interventions not 
covered in ongoing 
trials and comparison 
of health-related quality 
(HRQoL) in different 
treatments
What are the best 
treatments that cure or 
delay the progression 
(worsening) of primary 
sclerosing cholangitis 
(PSC)?
14 9 trials None of the trials include 
survival, HRQoL as 
outcomes¶
High-quality RCTs 
with clinical outcomes 
(survival, HRQoL)
What are the best 
treatments that cure or 
delay the progression 
(worsening) of non-
alcohol-related fatty 
liver disease (NAFLD)?
15 (Includes only 
pharmacological 
interventions)
More than 10 
published trials on 
lifestyle interventions 
and more than 20 
trials on nutritional 
supplementation with 
no recent high-quality 
systematic reviews
Pharmacological 
interventions
44 trials
Lifestyle interventions and 
nutritional supplementation
Not applicable as there are 
no high-quality systematic 
reviews
Pharmacological 
interventions
Health-related quality of 
life (2 trials), resolution of 
fatty liver disease (11 trials), 
mortality (2 trials), cirrhosis 
(2 trials), cardiovascular 
events (2 trials)¶
High-quality systematic 
reviews on lifestyle 
interventions (one 
review) and nutritional 
supplementation to 
cure or delay the 
progression of NAFLD 
and high-quality RCTs 
on pharmacological 
interventions with 
clinical outcomes 
(survival, HRQoL)
What is the best 
immunosuppressive 
regimen in adults 
undergoing liver 
transplantation?
16 (Covers only 
maintenance 
immunosuppression)
Induction 
immunosuppression: 
more than 20 published 
trials
Maintenance 
immunosuppression
4 trials
Induction 
immunosuppression
Not applicable as there is 
no high-quality systematic 
review
Maintenance 
immunosuppression
Graft survival (1 trial)
Adverse events (1 trial)
Hepatocellular carcinoma 
(1 trial)¶
High-quality systematic 
review on induction 
immunosuppressive 
regimen and high-
quality RCTs on 
maintenance 
immunosuppression 
with important clinical 
outcomes (overall 
survival, HRQoL)
Should general public 
be educated about 
NAFLD with an aim to 
reduce the numbers of 
those that have it?
None None - High-quality RCTs on 
education to prevent 
NAFLD
What are the best 
treatments that cure or 
delay the progression 
(worsening) of 
autoimmune hepatitis?
None 15 trials Survival (1 trial), health-
related quality of life (1 
trial)¶
High-quality RCTs 
with clinical outcomes 
(survival, HRQoL)
What are the best 
treatments that cure or 
delay the progression 
(worsening) of non-
alcohol-related 
steatohepatitis (NASH)?
The evidence related to this question is covered under NAFLD by performing a subgroup analysis of 
people with NASH
Continued
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their summary scores in each Delphi round along with 
similar summary measures for healthcare professionals.
DIsCussIOn
This is the first priority setting partnership on non-alco-
hol-related liver and gallbladder disorders. This included 
a wide range of disease processes and a total of 428 unique 
research questions that met the scope of this priority 
setting partnership were identified. All the research ques-
tions were considered unanswered as there had been no 
high-quality systematic reviews which indicated that no 
further research is required, that is, all the research ques-
tions were uncertainties. Consensus that an uncertainty 
was a very important research priority was reached for six 
research questions. Four additional research questions 
with the highest proportion of Delphi panel members 
ranking the question as highly important were added to 
constitute the top 10 research priorities.
As evident from the online supplementary appendix 1, 
longevity of life and health-related quality of life are two 
major outcomes that appear important to patients, their 
carers and healthcare professionals. However, even when 
there are ongoing trials, it appears that the outcomes in 
those trials will not address the outcomes listed in eight 
of the top 10 research questions (table 2). Therefore, the 
next step in addressing these uncertainties is the design 
and conduct of RCTs. Such RCTs may involve qualitative 
studies to determine the design and should compare 
the treatments that improve the longevity of life and/or 
health-related quality of life.
It should be noted that uncertainties ‘what are the 
best treatments that cure or delay the progression (wors-
ening) of NAFLD?’ and ‘what are the best treatments that 
cure or delay the progression (worsening) of non-alco-
hol-related steatohepatitis (NASH)?’ are related to each 
other. Although NAFLD includes NASH, most of the 
panel members felt that the research questions related 
to NAFLD and NASH should be kept separate uncertain-
ties. While the same systematic review can cover both the 
uncertainties, the primary research study designed to 
address these two questions differ in terms of the setting, 
the outcomes used and the period of follow-up. Any 
Treatment uncertainty 
(research question)
High-quality 
systematic review*†
RCTs not included 
in the systematic 
review*‡
Patient-oriented 
outcomes assessed in 
trials not included in the 
systematic review§ Next step
Prior to liver 
transplantation, is it 
better to transport the 
donor liver using a 
machine which pumps 
blood or preservation 
solution through 
the liver (machine 
perfusion) or is it 
better to transport it 
in the standard way 
of transporting it 
immersed in cold 
preservation solution 
(cold storage)?
None 5 trials Overall survival (4 trials), 
graft survival (5 trials), 
health-related quality of life 
(2 trials)
Await results of the 
RCTs (all expected to 
complete by the end 
of 2019) and perform a 
high-quality systematic 
review
What are the best 
treatments that cure or 
delay the progression 
(worsening) of primary 
biliary cholangitis?
17 24 trials Health-related quality of life 
(5 trials), relief of symptoms 
(5 trials)¶
High-quality RCTs 
with clinical outcomes 
(survival, HRQoL)
Are there any 
treatments that reverse 
the liver damage in 
PSC?
The evidence related to this question is covered under treatments for PSC. The systematic review 
did not include fibrosis as one of the outcomes. Nine of the trials included in the systematic review 
reported on fibrosis. Two of the trials not included in the systematic review (and listed above) reported 
on liver fibrosis
*Numbers indicate the reference number.
†Further well-designed randomised controlled trials (RCTs) using clinical outcomes were recommended by all these systematic reviews.
‡Ongoing trials, unpublished trials or trials published since the search date for the systematic review when a high-quality systematic review 
based on RCTs exists. If no systematic reviews based on RCTs exist, these are either published trials or ongoing studies.
§This information is reported to find out whether the important patient-oriented outcomes are reported in the trials not covered by high-quality 
systematic reviews. This is to help with deciding whether new RCTs are necessary on the topic.
¶The remaining trials reported treatment-related adverse events, composite outcomes and surrogate markers.
Table 2 Continued 
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primary research that tries to answer these two questions 
in a single RCT will be inefficient.
Similarly, for the uncertainties ‘what are the best treat-
ments that cure or delay the progression (worsening) of 
PSC’ and ‘are there any treatments that reverse the liver 
damage in PSC?’, a single RCT will be inefficient and the 
preference of most of the panel members was to keep 
these uncertainties as separate uncertainties.
There are several limitations to our priority setting 
process. The first one is deviation from the original 
protocol. To select the final top priorities, the initial 
plan was to arrive at consensus by open small group and 
large group discussions of patients, carers, and health-
care professionals as suggested by the standard JLA 
process,8 which provides an opportunity for a knowledge 
exchange of viewpoints and experience. However, part 
of the steering committee with experience in a similar 
priority setting partnership felt that open discussions 
resulted in ‘loud voices’ being given more importance 
resulting in an unrepresentative list of top priorities. 
While this can be mitigated by facilitated group discus-
sions by neutral JLA facilitators to ensure that all voices 
were heard in the discussions, this was considered by 
the steering committee as an important source of bias 
based on their prior experience in participating in open 
discussions. The steering committee therefore decided 
to follow the Delphi consensus method which is one 
of the major consensus methods.10 The advantages of 
Delphi consensus method over open discussions include 
anonymity of the response and the equal weight given to 
the opinions of all members.10 In addition, they are less 
costly to conduct without any limitation by geographical 
location compared with other methods of consensus10 
because of the lack of necessity to travel and take time 
off regular work. However, there is considerable vari-
ability in the previous performance of Delphi processes 
with regard to the number of rounds and the criteria for 
achieving consensus.11 Arriving at consensus depends on 
people revising their scores based on the other’s scores. 
Our initial plan was to extend the Delphi to four rounds 
if consensus on 10 top research priorities was not reached 
in three rounds. However, there was minimal change in 
scores between the rounds for most questions (online 
supplementary appendix 3) and the Delphi process was 
completed in three rounds. Consensus on a top research 
priority was achieved for six questions only. However, the 
proportion of Delphi panel members ranking a ques-
tion as highly important was greater than 70% for the 
remaining four questions added to the list of top research 
priorities. Previous Delphi consensus processes have used 
various cut-off points for defining consensus: greater than 
70% agreement among panel members is well within the 
definition of consensus used in previous Delphi consensus 
processes.11
The other major limitation of our priority setting 
process is the representativeness of the people who 
completed the survey and took part in the Delphi 
process. The online survey was shared among clinicians 
and members of general and disease-specific patient 
organisations. Most questions resulting from the online 
survey relate to chronic liver disease (in particular, auto-
immune liver diseases), perhaps reflecting the high moti-
vation to support research from those groups. The Delphi 
panel also had a high representation of people related 
to chronic liver disease (in particular, autoimmune liver 
diseases) as patients, carers or healthcare professionals. 
While people affected by different liver and gallbladder 
disorders were actively sought through both general 
and disease-specific patient support groups and organ-
isations, only a few responded and completed all three 
rounds of the Delphi process. The potential bias towards 
prioritising chronic liver diseases is evident as nine of the 
top 10 research priorities relate to chronic liver diseases 
(four relate to autoimmune liver diseases, three related 
to NAFLD and two related to liver transplantation). It was 
surprising that the uncertainties related to the treatment 
of chronic viral diseases such as chronic hepatitis B and 
chronic hepatitis C were not identified within the top 10 
research priorities. This may be because of the percep-
tion by some of the panel members that the research 
questions related to the treatment of chronic hepatitis C 
were answered with the advent of directly acting antivirals 
(personal communication). The reason for non-priori-
tisation of chronic hepatitis B is not entirely clear. This 
may be because chronic hepatitis B may not have been 
considered as important as other chronic liver diseases or 
under-representation of chronic hepatitis B in the panel.
Cancer-related questions, childhood-related liver 
diseases and other benign disorders did not end up in 
the top research priorities (except for the treatment of 
very early hepatocellular carcinoma, which is managed 
by hepatologists and surgeons) probably for the reasons 
described above. We recommend that separate prioritisa-
tion processes are carried out for people with gallstones, 
a condition that affects approximately 5%–25% of the 
population,12 for people with primary and secondary liver 
cancer, and childhood liver disorders where significant 
uncertainties remain on the effectiveness of different 
treatments in decreasing mortality and improving 
health-related quality of life.
As well as the above limitation, we are aware of the 
inherent limitations of using solely technology to carry 
out the Delphi exercise. These are limitations that can 
potentially lead to bias in any consensus-building method 
including that of face-to-face consensus methods normally 
used in a JLA PSP.
One solution which might address the limitations of 
this priority setting process and the standard JLA process 
may be to collect information routinely from patients 
visiting hospitals using paper forms and conduct online 
meetings (video conferencing and presentation) before 
the final round of the Delphi (or the standard face-to-
face priority setting workshop used by the JLA. Some JLA 
PSPs do use methods such as face-to-face interviews and 
group discussions rather than solely online surveys). By 
collecting information on paper forms and conducting 
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the meetings in hospitals, it is possible to engage with 
people who do not have access to or are not familiar with 
computers. It is also possible to engage with people who 
have concerns regarding data confidentiality with the 
use of computers or social media by collecting informa-
tion using paper forms. Ethical and confidentiality issues 
will need to be considered prior to engaging patients 
attending hospital in the research prioritisation process.
Another limitation of our priority setting process is the 
drop-outs during the Delphi process. While some of the 
drop-outs may be related to the ability to complete online 
surveys and use Microsoft Excel, some patient representa-
tives or clinicians may have dropped out because they did 
not find any research question to be of direct relevance to 
them. Other reasons include lack of understanding of the 
conditions, feeling that the process was too complicated, 
feeling that the process would not work, and the time 
commitment for the process. This is because of the broad 
scope of this research prioritisation process and may be 
overcome by choosing a narrower focus while defining the 
scope of the prioritisation process, and by better explana-
tion of the disease processes through presentations.
It should also be recognised that the Delphi panel was 
constituted of representatives from England, Scotland 
and Wales. Therefore, the findings are applicable in only 
these countries. However, the findings are likely to be 
applicable throughout the NHS and in other European 
and Western countries with a similar spectrum of chronic 
liver diseases and similar treatment options available.
In summary, there are significant uncertainties in the 
management of liver and gallbladder disorders. Further 
high-quality research is necessary to address these uncer-
tainties which may require programmes of basic, trans-
lational, clinical and public health research. For issues 
with diverse and unproven treatment options, RCTs may 
be the only mechanism for identifying the most effective 
treatment and the treatments that represent good value 
for money for the NHS. Such RCTs should assess the 
effect of different treatments in improving longevity of 
life and/or health-related quality of life.
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